Arvinas Dettes/EBITDA

Que fait Arvinas ? Arvinas Inc. is a biopharmaceutical company based in New Haven (Connecticut, USA). The company was founded in 2013 by Dr. Craig Crews, who also serves as a scientific advisor to the company. The company's mission is to develop innovative therapies based on Proteolysis-Targeting Technology (PROTAC). This technology uses artificially created molecules to recognize and label specific proteins in the body, which are then broken down by the body's enzymes. This allows for the treatment of diseases caused by faulty folded or overexpressed proteins. Arvinas' business model is to develop multiple drug candidates based on this platform. The company collaborates with leading academic institutions and biotechnology companies to identify targets that can be reached using PROTAC technology. In addition, the company has a proprietary pipeline of drug candidates in various stages of clinical development. Arvinas operates in several therapeutic areas, including cancer, immunology, and metabolic diseases. The company's drug candidates include ARV-110, a PROTAC targeting the androgen receptor protein (AR). ARV-110 is a potential therapeutic approach for patients with resistant prostate cancer. Similarly, other drug candidates from Arvinas also target specific proteins associated with certain diseases. Another drug from the company is ARV-471, an orally administered "degrader" that targets the estrogen receptor alpha (ERa) associated with breast cancer. ARV-471 is a potential therapeutic approach for patients with rare subtypes of breast cancer. Arvinas also has partnerships in various areas of drug development. For example, in collaboration with Pfizer, ARV-411, a PROTAC targeting the menin-1 protein associated with acute myeloid leukemia, is being developed. Arvinas also has a partnership with Genentech, a subsidiary of the pharmaceutical company Roche, for the use of PROTAC in the treatment of cancer. Overall, Arvinas is an innovative biopharmaceutical company based on Proteolysis-Targeting Technology, focusing on the development of comprehensive therapeutic approaches. Through numerous partnerships and a diverse pipeline, the company is well-positioned to play a significant role in drug development. Arvinas est l'une des entreprises les plus populaires sur Eulerpool.